Vnitr Lek 2021, 67(2):97-102 | DOI: 10.36290/vnl.2021.021

Current view of diagnosis and treatment of latent autoimmune diabetes in adults

Jana Urbanová1, Ludmila Brunerová1, Jana Malinovská2, Barbora Pelechová2, Ludmila Koberová2, Jan Brož2
1 Centrum pro výzkum diabetu, metabolismu a výživy, II. interní klinika 3. LF UK a FNKV Praha
2 Interní klinika FN v Motole a 2. LF UK, Praha

Latent Autoimmune Diabetes in Adults (LADA) is an autoimmune disease arising at adulthood. LADA is characterized by a less intensive autoimmune process, slower progression and a mild metabolic decompensation at onset compared with young-onset type 1 diabetes mellitus. The onset of LADA is usually in non-obese patients over 30, without prominent features of metabolic syndrome and insulin resistance. Nevertheless it may be falsely classified as type 2 diabetes, especially, when diagnosed in older age and for the possibility of non-insulin treatment for at least 6 months after diagnosis. LADA is treated early with insulin and combined with metformin in patients with a higher level of insulin resistance. Clinical studies suggested also effectivity of other oral antidiabetics enabling preservation of residual β-cell function, such as particularly incretines.

Keywords: diabetes mellitus, diagnosis, GADA, LADA, therapy.

Published: April 21, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbanová J, Brunerová L, Malinovská J, Pelechová B, Koberová L, Brož J. Current view of diagnosis and treatment of latent autoimmune diabetes in adults. Vnitr Lek. 2021;67(2):97-102. doi: 10.36290/vnl.2021.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pozzilli P, Pieralice S. Latent Autoimmune Diabetes in Adults: Current Status and New Horizons. Endocrinol Metab (Seoul). 2018; 33(2): 147-159. Go to original source... Go to PubMed...
    2. Šumník Z, Průhová Š. LADA and MODY: How do we know them? Med. Praxi 2016, 13(1): 26-29. Go to original source...
    3. Mojto V. Monogénne formy diabetu mellitu a latentný autoimunitný diabetes u dospelých: Monogenic forms of diabetes mellitus and latent autoimmune diabetes in adults. Lekársky obzor: HERBA, 2013, 62(9), 346-349.
    4. Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes Front. Physiol., 26 March 2019 | https://doi.org/10.3389/fphys.2019.00320 Go to original source... Go to PubMed...
    5. Naik RG, Brooks‑Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94(12): 4635-4444. Go to original source... Go to PubMed...
    6. Buzzetti R, Zampetti S, Maddaloni E. Adult‑onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13(11): 674-686. Go to original source... Go to PubMed...
    7. Hawa MI, Kolb H, Schloot N et al., Action LADA consortium.Adult‑onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36(4): 908-913. Go to original source... Go to PubMed...
    8. Yang Z et al. Childhood diabetes in China. Enormous variation by place and ethnic group. Diabetes Care 1998; 21: 525-529. Go to original source... Go to PubMed...
    9. Lampasona V, Petrone A, Tiberti C et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult‑onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010; 33: 104-108. Go to original source... Go to PubMed...
    10. Heneberg P, Šimčíková D, Čecháková M et al. Autoantibodies against ZnT8 are rare in Central‑European LADA patients and absent in MODY patients, including those positive for other autoantibodies. Journal of Diabetes and its Complications. 2019 Jan; 33(1): 46-52. DOI: 10.1016/j.jdiacomp.2018. 10. 004. Go to original source... Go to PubMed...
    11. Buzzetti R, Di Pietro S, Giaccari A et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult‑onset autoimmune diabetes. Diabetes Care 2007; 30: 932-938. Go to original source...
    12. Maddaloni E, Lessan N, Al Tikriti A, et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin‑requirement. PLoS One. 2015; 10: e0131837. Go to original source... Go to PubMed...
    13. Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am. 2015 Jan; 99(1): 1-16 Go to original source... Go to PubMed...
    14. Fourlanos S, Perry C, Stein MS et al. A Clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006; 29: 970-975. Go to original source...
    15. Zampetti S et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow‑up (NIRAD study 7). Eur J Endocrinol 2014; 171, 697-704. Go to original source... Go to PubMed...
    16. Zhou Z et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult‑onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2005; 21, 203-208. Go to original source... Go to PubMed...
    17. Scheen AJ. Suspension of the commercialization of sibutramine and rosiglitazone in Europe. Rev Med Liege 2010; 65 (10): 574-579. Go to PubMed...
    18. Kobayashi T, Nakanishi K, Murase T et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta‑cell failure in islet cell antibody‑positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622-626. Go to original source... Go to PubMed...
    19. Maruyama, T. et al. Insulin intervention in slowly progressive insulin‑dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2115-2121. Go to original source... Go to PubMed...
    20. Zhao, Y. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β‑cell function in patients with recent‑onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014; 99: E876-E880. Go to original source... Go to PubMed...
    21. Johansen OE, Boehm B, Grill V et al. Beta‑cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: exploratory results from a 2-year double‑blind randomized controlled study. Endocr Rev. 2012; 33(4 Suppl): SUN-LB1. Go to original source... Go to PubMed...
    22. Buzzetti R, Pozzilli P, Frederich R et al. Saxagliptin improves glycaemic control and C‑peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev 2016; 32: 289-296. Go to original source... Go to PubMed...
    23. Jones AG, McDonald TJ, Shields BM et al. for the PRIBA Study Group. Markers of β‑Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care 2016 Feb; 39(2): 250-257. Go to original source... Go to PubMed...
    24. Pozzilli P, Leslie RD, Peters AL et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post‑hoc analysis of the AWARD-2, -4 and -5 trials. Diabetes Obes Metab 2018; 20: 1490-1498. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.